Literature DB >> 21239753

Malignancies in juvenile idiopathic arthritis: a preliminary report.

Sasha Bernatsky1, Alan M Rosenberg, Kiem G Oen, Ciaran M Duffy, Rosalind Ramsey-Goldman, Jeremy Labrecque, Yvan St Pierre, Ann E Clarke.   

Abstract

OBJECTIVE: To present preliminary data on incidence of malignancy in juvenile idiopathic arthritis (JIA), compared to general population rates.
METHODS: We examined cancer occurrence within JIA registries at 3 Canadian pediatric rheumatology centers. The subjects in the clinic registries were linked to regional tumor registries to determine the occurrence of invasive cancers over the observation period (spanning 1974-2006). The total number of cancers expected was determined by multiplying the person-years in the cohort by age, sex, and calendar year-specific cancer rates. The standardized incidence ratio (SIR, ratio of cancers observed to expected) was generated, with 95% confidence intervals.
RESULTS: The study sample consisted of 1834 patients. The female proportion was 67.6%; average age at entry to cohort was 8.6 years (SD 5.1). The majority were Caucasian. Subjects contributed 22,341 patient-years (average 12.2, SD 7.8). Within this observation period, one invasive cancer occurred, compared to 7.9 expected (SIR 0.12, 95% CI 0.0, 0.70). This was a hematological cancer (Hodgkin's lymphoma), representing a SIR for hematological malignancies of 0.76 (95% CI 0.02, 4.21).
CONCLUSION: Only one invasive cancer was identified in this large sample of individuals with JIA, observed for an average of 12.2 years each. These data suggest that, at least in the initial years following diagnosis of JIA, the risk of invasive cancers overall is not markedly increased. The results do not rule out the possibility of a baseline increased risk of hematological malignancies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21239753     DOI: 10.3899/jrheum.100711

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  20 in total

Review 1.  The humanistic and economic burden of juvenile idiopathic arthritis in the era of biologic medication.

Authors:  Wendy Gidman; Rachel Meacock; Deborah Symmons
Journal:  Curr Rheumatol Rep       Date:  2015-05       Impact factor: 4.592

2.  Juvenile idiopathic arthritis: management and therapeutic options.

Authors:  Natasha M Ruth; Murray H Passo
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-04       Impact factor: 5.346

Review 3.  Advances from clinical trials in juvenile idiopathic arthritis.

Authors:  Daniel J Lovell; Nicola Ruperto; Edward H Giannini; Alberto Martini
Journal:  Nat Rev Rheumatol       Date:  2013-07-09       Impact factor: 20.543

4.  Rates of malignancy associated with juvenile idiopathic arthritis and its treatment.

Authors:  Timothy Beukelman; Kevin Haynes; Jeffrey R Curtis; Fenglong Xie; Lang Chen; Christina J Bemrich-Stolz; Elizabeth Delzell; Kenneth G Saag; Daniel H Solomon; James D Lewis
Journal:  Arthritis Rheum       Date:  2012-02-10

Review 5.  What is the background incidence of malignancy in children with rheumatic disease?

Authors:  Melissa L Mannion; Timothy Beukelman
Journal:  Curr Rheumatol Rep       Date:  2013-03       Impact factor: 4.592

Review 6.  Using registries to identify adverse events in rheumatic diseases.

Authors:  Geraldina Lionetti; Yukiko Kimura; Laura E Schanberg; Timothy Beukelman; Carol A Wallace; Norman T Ilowite; Jane Winsor; Kathleen Fox; Marc Natter; John S Sundy; Eric Brodsky; Jeffrey R Curtis; Vincent Del Gaizo; Solomon Iyasu; Angelika Jahreis; Ann Meeker-O'Connell; Barbara B Mittleman; Bernard M Murphy; Eric D Peterson; Sandra C Raymond; Soko Setoguchi; Jeffrey N Siegel; Rachel E Sobel; Daniel Solomon; Taunton R Southwood; Richard Vesely; Patience H White; Nico M Wulffraat; Christy I Sandborg
Journal:  Pediatrics       Date:  2013-10-21       Impact factor: 7.124

Review 7.  Biologics in Pediatric Rheumatology: Quo Vadis?

Authors:  Yonit Sterba; Norman Ilowite
Journal:  Curr Rheumatol Rep       Date:  2016-07       Impact factor: 4.686

8.  Current medical treatments for juvenile idiopathic arthritis.

Authors:  Nicolino Ruperto; Alberto Martini
Journal:  Front Pharmacol       Date:  2011-10-10       Impact factor: 5.810

Review 9.  Role of adalimumab in the management of children and adolescents with juvenile idiopathic arthritis and other rheumatic conditions.

Authors:  Katherine Anne B Marzan
Journal:  Adolesc Health Med Ther       Date:  2012-06-20

Review 10.  Clinical utility of etanercept in the treatment of arthritides in children and adolescents.

Authors:  Robin K Dore
Journal:  Adolesc Health Med Ther       Date:  2014-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.